Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice

Therapies targeting DNA and RNA in Huntington's disease

(2017) Edward J Wild et al.   LANCET NEUROLOGY

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

(2017) Lauren M Byrne et al.   LANCET NEUROLOGY

NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration

(2017) Anthony Brureau et al.   NEUROBIOLOGY OF DISEASE

Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models

(2017) Amalie Clement et al.   NEUROSCIENCE

Huntington’s Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits

(2017) Ryan G. Lim et al.   Cell Reports

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Neurofilament dynamics and involvement in neurological disorders

(2015) Benoit J. Gentil et al.   CELL AND TISSUE RESEARCH

Animal models of Huntington's disease for translation to the clinic: Best practices

(2014) Liliana Menalled et al.   MOVEMENT DISORDERS

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

(2011) Sarah J Tabrizi et al.   LANCET NEUROLOGY

Huntington's Disease: Can Mice Lead the Way to Treatment?

(2011) Zachary R. Crook et al.   NEURON

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

(2010) Sarah J Tabrizi et al.   LANCET NEUROLOGY

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

(2010) David M Rissin et al.   NATURE BIOTECHNOLOGY

Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study

(2010) D. Stoffers et al.   NEUROLOGY

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders

(2009) Radu Constantinescu et al.   PARKINSONISM & RELATED DISORDERS

The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: Influence of non-motor factors on locomotor function

(2008) Patrick N. Pallier et al.   BRAIN RESEARCH BULLETIN

Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice

(2008) A Jennifer Morton et al.   NEUROBIOLOGY OF DISEASE